The Pharma week,distilled.

Isomorphic Labs, a London-based AI drug discovery spinout from Google DeepMind, is reportedly in negotiations to raise new capital at a valuation between $40 billion and $50 billion.

City, a developer of RNAi therapeutics, has priced its initial public offering at $200 million.

Biogen-backed biotech company Estuary has secured $93 million in a Series A funding round.

OMass Therapeutics has secured $310 million in a Series C funding round.

Iambic, an AI-driven drug discovery company, has announced plans to raise $150 million through an initial public offering.

OMass Therapeutics Ltd. has raised $310 million in a Series C funding round, marking one of the largest venture investments for a U.K.-based biotech company.

Also: 18 Oct — medcitynews.com

Belgian startup Armed Cell Therapeutics has acquired cell therapy assets from Lakefront Biotherapeutics, formerly known as Galapagos.

Liquidia has agreed to pay approximately $380.7 million to United Therapeutics to settle six lawsuits regarding patent infringement, trade secrets, and antitrust claims.

Epic is launching a new tool called Prescription Marketplace in summer 2027 to help clinicians and patients compare medication costs, including cash prices and insurance-covered rates.

The FDA approved Roche's Enspryng (satralizumab) on October 16, 2026, as a subcutaneous treatment for adults with thyroid eye disease.

Walmart announced an overhaul of its employee benefits package effective in 2027 for its 1.6 million U.S. employees.

Google DeepMind researchers, including Pengfei Tian and Lucy J. Colwell, introduced Google Antigravity, an agentic science workbench designed to accelerate the discovery of antimicrobial peptides.

The U.S. Food and Drug Administration approved the sunscreen ingredient bemotrizinol (BEMT) in June 2026.

Bizon Labs, a spin-off company from the Massachusetts Institute of Technology (MIT), has been established to improve the manufacturing process of lipid nanoparticles (LNP).

Oklo has announced plans for its next reactor project, Groves-2 Forge, located in Lockhart, Texas.

FedEx Corp. has launched a new digital portal for its FedEx Temp-Assure Advantage (FTAA) service in Europe to streamline the booking and management of temperature-controlled pharmaceutical shipments.

City Therapeutics and Iambic Therapeutics completed their initial public offerings in the US, raising $200 million and $150 million respectively.

The article provides a market analysis of mid-cap biopharmaceutical companies in 2026, highlighting Iovance Biotherapeutics as a top performer.

City Therapeutics Inc. completed an upsized $200 million IPO on NASDAQ, pricing shares at $18.

Iambic Therapeutics CEO Tom Miller discussed the company's recent $150 million IPO and the future of AI in drug development.

Eli Lilly has reached a $1 trillion market valuation, largely driven by the success of its GLP-1 weight-loss and diabetes medications.

JPMorgan analyst Chris Schott upgraded Biogen stock from Neutral to Overweight on October 12, 2026, raising the price target from $210 to $300.

Venture capital investment in biopharmaceutical companies dropped to $6.44 billion in the third quarter of 2026 from $10.17 billion in the second quarter, according to data from Evaluate.

LATAM Cargo reported a 150% increase in pharmaceutical air shipments between Europe and Brazil during the first seven months of 2026 compared to the same period in 2025.

Liquidia and United Therapeutics have reached a settlement to resolve six lawsuits involving patent infringement, trade secrets, and antitrust claims.

The founder of Done Global was sentenced to six years in prison for illegally distributing 37 million Adderall pills.

CVS Health has agreed to pay $315 million to settle allegations regarding the filling of unnecessary opioid prescriptions.

CVS Health has agreed to pay $315 million to settle a Department of Justice investigation regarding opioid distribution.

Bank of America has agreed to pay $1.2 billion to settle allegations regarding violations of money laundering and sanctions laws.

McDermott Will & Emery attorneys summarized 340B drug pricing litigation developments occurring between October 6 and October 12, 2026, across the United States.

Researchers from Seoul National University analyzed health data from over 4.5 million Korean adults to study the link between vaping and lung cancer.

French biotech company Osivax is shifting its development strategy toward a combination vaccine approach following the failure of its standalone influenza vaccine candidate in a phase 2 clinical trial.

Researchers at the Massachusetts Institute of Technology, led by Li-Huei Tsai, discovered that the APOE4 gene variant disrupts Wnt signaling in oligodendrocytes, leading to impaired myelin production in the brain.

Researchers have developed a method to initiate mouse embryogenesis using chemically induced totipotent-like stem cells (ciTotiSCs).

Researchers have utilized RFdiffusion methods to de novo design metalloproteases capable of cleaving specific human disease-associated proteins, including TDP-43, amyloid-β, and serum amyloid A. Out of 135 tested designs, 36% successfully catalyzed peptide bond cleavage, with the most effective design achieving a 10^10-fold acceleration of hydrolysis. The study, published in Nature on October 14, 2026, also demonstrates the creation of caged cytokines and receptor antagonists activated by these proteases.

Researchers have developed a new myosin-specific and capillary-selective vasodilator drug, R(+)2501, to treat capillary no-reflow in acute myocardial infarction and acute kidney injury.

Arrowhead Pharmaceuticals has reported that its experimental RNA interference drug successfully crossed the blood-brain barrier in a clinical study.